CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT01225146
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:28.380227+00:00
Published At: 2017-08-14T00:00:00+00:00
Record Updated At: 2017-08-14
Results Posted At: 2017-08-14
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Ischemia", "Retinal Vein Occlusion", "Pathologic Processes", "Retinal Diseases", "Eye Diseases"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2017-08-14"
protocolSection.identificationModule.nctId: "NCT01225146"
protocolSection.identificationModule.officialTitle: "A Phase I Open Label Study of the Safety, Tolerability and Efficacy of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2017-08-14"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.